Q going forward? Because we saw this with, uh, GLP ones. I mean, I'm sure, or CRISPR, these stuff, this stuff was NIH funded at one point. There was a ton of research, and then we get this big boom, like, but it's 10 years later. What's on the frontier? What are you most excited about? And what should we be fighting for? Let's keep the funding there no matter what.
A Yeah. Great, great question. Uh, in fact, the most important question. So regardless of whether or not this 40% cut happens, if it's less, if it's kept the same, um, a couple of things. First of all, despite the fact that NIH funds basic research and that many laboratories, including my own for, for many years, focused on basic research, like how does the visual system work? We always had an eye. Every laboratory has an eye toward, you know, what, what the translational implications could be. Okay. So we were actively involved in trying to solve You know, blindness due to glaucoma, even though we were focusing on some basic questions. So I think it, it, it's a statistical issue. If you step back and you say, okay, in the field of, let's just say vision, my, my former field, um, what is the leading cause of blindness? Cataract. But you know what? You can fix cataract. You can slide out the lens and you put in a new lens that's being done now.
AI assessment note: “actively involved in trying to solve You know, blindness due to glaucoma”